STOCK TITAN

Centogene NV - CNTG STOCK NEWS

Welcome to our dedicated news page for Centogene NV (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Centogene NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Centogene NV's position in the market.

Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) has formed a new joint venture (JV) with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), to provide state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region. The JV, Lifera Omics, located in Riyadh, Saudi Arabia, will receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. CENTOGENE will have an 80% ownership structure in Lifera Omics and will be eligible for performance-related milestone payments and revenue-based royalties until the year 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced the discovery of a new form of early-onset dystonia and parkinsonism related to the ACBD6 gene. The landmark study published in Brain journal reveals that bi-allelic pathogenic variants in the ACBD6 gene lead to a distinct neurodevelopmental syndrome with complex cognitive and movement disorders. The study identified 45 patients from 29 families across the globe and aims to guide further research for potential treatments and to understand genetic causes and pathways leading to Parkinson’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none
-
Rhea-AI Summary
Centogene expands MOx diagnostic portfolio with RNA sequencing for better disease understanding
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
Rhea-AI Summary
Centogene N.V. CEO to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences
-
Rhea-AI Summary
Centogene N.V. reports strong revenues and steady growth in both diagnostics and pharma segments. Total revenues for H1 2023 increased by 15.1% to €24.6 million. Diagnostics segment revenues increased by 12.7% to €16.3 million, driven by an increase in test requests. Pharma segment revenues increased by 20.3% to €8.3 million. Operating loss decreased to €21.3 million. Total segment adjusted EBITDA decreased by 45.3% to €2.9 million. Cash and cash equivalents were €14.2 million as of June 30, 2023. Strategic collaboration with Lifera secures $30 million investment and approx. $50 million in upfront payment and milestones. Positive financial performance reaffirms full year 2023 revenue growth guidance of 10% to 15%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
earnings
-
Rhea-AI Summary
Results confirm lyso-Gb1 as a sensitive biomarker for Gaucher disease, predicting clinical course and improving personalized care. Significant correlation found between lyso-Gb1 levels and disease severity. Study sets standard for Gaucher disease care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
none
Rhea-AI Summary
Centogene N.V. receives notification from Nasdaq regarding non-compliance with minimum Market Value of Publicly Held Shares requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
-
Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) has regained compliance with Nasdaq listing standards, meeting the minimum bid price and Market Value of Publicly Held Shares requirements. The company was previously notified of non-compliance due to its stock failing to meet the closing bid price of USD 1.00 for 30 consecutive business days and not meeting the minimum MVPHS of USD 15 million. However, as of July 12, 2023, the bid price requirement was met, and as of July 13, 2023, the MVPHS requirement was also fulfilled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
none
Centogene NV

Nasdaq:CNTG

CNTG Rankings

CNTG Stock Data

19.23M
9.60M
2.73%
65.22%
0.09%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Germany
Rostock

About CNTG

centogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2800 genes, biochemical tests, biomarker tests, clinical whole exome sequencing and whole genome sequencing. centogene’s mission is to support medical professionals with in-depth medical expertise in order to diagnose early the cause of the patients’ symptoms. analyzing samples from all over the world allows centogene to constantly expand its unique portfolio resulting in the largest systematic documentation of genetic results, centomd®. this mutation database integrates genetic and clinical information, enabling the highest quality, knowledge-based genetic testing and biomarker development. in addition to offering diagnostic services for individual patients, centogene is a pivotal partner to some of the most respected names in the industry. imprint centogene ag is a stock corporation ('aktiengesellschaft') incorporated under the